11-116790235-CTGTT-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_001371904.1(APOA5):βc.990_993delβ(p.Asp332ValfsTer5) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000805 in 1,614,144 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ).
Frequency
Genomes: π 0.0000066 ( 0 hom., cov: 34)
Exomes π: 0.0000082 ( 0 hom. )
Consequence
APOA5
NM_001371904.1 frameshift
NM_001371904.1 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.0360
Genes affected
APOA5 (HGNC:17288): (apolipoprotein A5) The protein encoded by this gene is an apolipoprotein that plays an important role in regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq, Oct 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.101 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-116790235-CTGTT-C is Pathogenic according to our data. Variant chr11-116790235-CTGTT-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 978324.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
APOA5 | NM_001371904.1 | c.990_993del | p.Asp332ValfsTer5 | frameshift_variant | 3/3 | ENST00000227665.9 | NP_001358833.1 | |
APOA5 | NM_001166598.2 | c.990_993del | p.Asp332ValfsTer5 | frameshift_variant | 4/4 | NP_001160070.1 | ||
APOA5 | NM_052968.5 | c.990_993del | p.Asp332ValfsTer5 | frameshift_variant | 4/4 | NP_443200.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
APOA5 | ENST00000227665.9 | c.990_993del | p.Asp332ValfsTer5 | frameshift_variant | 3/3 | 1 | NM_001371904.1 | ENSP00000227665 | P1 | |
APOA5 | ENST00000433069.2 | c.990_993del | p.Asp332ValfsTer5 | frameshift_variant | 4/4 | 1 | ENSP00000399701 | P1 | ||
APOA5 | ENST00000542499.5 | c.990_993del | p.Asp332ValfsTer5 | frameshift_variant | 4/4 | 5 | ENSP00000445002 | P1 | ||
APOA5 | ENST00000673688.1 | c.1074_1077del | p.Asp360ValfsTer5 | frameshift_variant | 3/3 | ENSP00000501141 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152254Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
1
AN:
152254
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251382Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135910
GnomAD3 exomes
AF:
AC:
2
AN:
251382
Hom.:
AF XY:
AC XY:
2
AN XY:
135910
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461890Hom.: 0 AF XY: 0.00000825 AC XY: 6AN XY: 727244
GnomAD4 exome
AF:
AC:
12
AN:
1461890
Hom.:
AF XY:
AC XY:
6
AN XY:
727244
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152254Hom.: 0 Cov.: 34 AF XY: 0.0000134 AC XY: 1AN XY: 74380
GnomAD4 genome
AF:
AC:
1
AN:
152254
Hom.:
Cov.:
34
AF XY:
AC XY:
1
AN XY:
74380
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Jan 21, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change creates a premature translational stop signal (p.Asp332Valfs*5) in the APOA5 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 35 amino acid(s) of the APOA5 protein. This variant is present in population databases (rs774150500, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with APOA5-related conditions (PMID: 23307945, 24591733, 29748148, 30420299; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as p.Q330Q fs X6. ClinVar contains an entry for this variant (Variation ID: 978324). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects APOA5 function (PMID: 23307945). For these reasons, this variant has been classified as Pathogenic. - |
Hypertriglyceridemia 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | DASA | Feb 14, 2022 | The c.990_993del;p.(Asp332Valfs*5) is a null frameshift variant in the APOA5 gene and predicts alteration of the nonsense-mediate decay - NMD is present in a relevant exon to the transcript - PVS1_moderate. Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product (PMID: 23307945) - PS3_supporting. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (PMID: 24591733; 28951076; 24291057) - PS4_moderate. This variant is not present in population databases (rs774150500, gnomAD; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2. The p.(Asp332Valfs*5) was detected in trans with a pathogenic variant (PMID: 24591733) - PM3. In summary, the currently available evidence indicates that the variant is likely pathogenic. - |
Familial type 5 hyperlipoproteinemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 23, 2023 | The c.990_993delAACA variant, located in coding exon 3 of the APOA5 gene, results from a deletion of 4 nucleotides at nucleotide positions 990 to 993, causing a translational frameshift with a predicted alternate stop codon (p.D332Vfs*5). This alteration occurs at the 3' terminus of theAPOA5 gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 35 amino acids (9.6%) of the protein. However, premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). This variant has been detected in the homozygous state and the in the compound heterozygous state with a second APOA5 pathogenic variant in individuals with severe hypertriglyceridemia (Mendoza-Barberá E et al. J Lipid Res, 2013 Mar;54:649-661; Hooper AJ et al. Ann Clin Biochem, 2014 Jul;51:485-9). This variant has also been detected in the heterozygous state in additional hypertriglyceridemia cohorts (Martín-Campos JM et al. Clin Chim Acta, 2014 Feb;429:61-8; Jin JL et al. EBioMedicine, 2018 Dec;38:171-177). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at